Faslodex

Type: Product
Name: Faslodex
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

It is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca PLC (NYSE: AZN) is trading higher on Monday chatter that Pfizer Inc. (NYSE: PFE) ... [Published 24/7 Wall St - Apr 21 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Engineers - Variety of Permanent/Fixed Term opportunities

AstraZeneca's Macclesfield site, located in Cheshire, in the North West of England, is the second largest manufacturing and supply site in the AstraZeneca network. The site is the European Regional packing hub, Global Stability and European Import testing ... [Published PharmaDiversity - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race

SummaryPalbociclib’s overall survival rate is not statistically significant but Pfizer is still the leader. Competitors Novartis and Eli Lilly are working hard to catch up. Sell Pfizer? Some thoughts.Palbociclib updateEarly approval hopes of palbociclib, ... [Published Seeking Alpha - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism. Chief executive Pascal Soriot stressed that 2013 had been a year of ‘momentum’ for the company and outlined three core therapy areas for 201, including ... [Published Pharma Letter - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Encouraging Results from Pfizer's Palbociclib - Analyst Blog

Pfizer Inc. (NYSE: PFE) announced positive detailed results from the phase II PALOMA-1 study on its oncology candidate, palbociclib. The study evaluated post-menopausal women suffering from estrogen receptor positive (ER+), human epidermal growth factor ... [Published Benzinga.com - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 3 reports

Encouraging Results from Pfizer's Palbociclib

Pfizer Inc. (PFE) announced positive detailed results from the phase II PALOMA-1 study on its oncology candidate, palbociclib. The study evaluated post-menopausal women suffering from estrogen receptor positive (ER+), human epidermal growth factor receptor ... [Published Yahoo! News - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 07 2014 - 1 reports

1 Experimental Breast Cancer Drug You Need to Know

Next to prostate cancer in men, breast cancer lands as the second most-prevalent cancer diagnosis in the United States, with nearly 235,000 estimates cases per year, according to the American Cancer Society. Breast cancer is also the second deadliest ... [Published Motley Fool Discussion Boards - Apr 06 2014]
First reported Mar 28 2014 - Updated Mar 29 2014 - 2 reports

AstraZeneca Has a Promising Oncology Pipeline

March 28, 2014, 12:09:48 PMAstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive  Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.In oncology, olaparib for solid tumours, moxetumomab ... [Published American Journal of Managed Care - Mar 28 2014]
First reported Jan 22 2014 - Updated Jan 22 2014 - 1 reports

Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving ... [Published PharmCast - Jan 22 2014]
First reported Dec 30 2013 - Updated Dec 30 2013 - 1 reports

Higher Dose of Faslodex Effective in Advanced Breast Cancer

Home » Syndicated Content » The final results are in—and they show that 500 mg of Faslodex® (fulvestrant) provides a significant advantage in overall survival compared to 250 mg of the drug in postmenopausal women with locally advanced or metastatic estrogen ... [Published BioPortfolio - Dec 30 2013]
First reported Nov 08 2013 - Updated Nov 08 2013 - 1 reports

2014 Pipeline Report: The Sprint to Value

Cancer: Multiple TargetsGenome-guided tumor diagnostics and treatments with the power to manipulate a patient's immune response have the potential to impact cancer outcomes in dramatic fashion. At the Cleveland Clinic's recent Medical Innovations Summit ... [Published Pharmaceutical Executive - Nov 08 2013]

Quotes

Buffett says that the percentage of total market cap (TMC) relative to the U S GNP is "probably the best single measure of where valuations stand at any given moment."
...palbo's 46%," noted Leerink's Seamus Fernandez in a statement after he sized up the Phase I results. "We maintain our LY2835219 peak 2026 sales forecast of $650M, with meaningful upside potential based on continually strong results / the success of combination trials, and potential expansion into add'l Rb-mediated tumors."
Nunn also noted that "colleagues at Novartis are combining their PI3 kinase inhibitor BKM120 with Faslodex in patients With HR+,HER2-, AI-treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor therapy” (the BELLE-3 study)."
...trials for gastric cancer, which raises the question: is there a true mechanistic difference in targeting the receptor versus the ligand? If so, "these angiogenics will start to separate themselves in terms of where they might be active" says Hawthorne. Sanofi/Regeneron haven't announced plans to test Zaltrap in gastric cancer, but http://ClinicalTrial...

More Content

All (17) | News (17) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
What a Combined Pfizer and AstraZeneca Would Lo... [Published 24/7 Wall St - Apr 21 2014]
Engineers - Variety of Permanent/Fixed Term opp... [Published PharmaDiversity - Apr 15 2014]
Pfizer Vs. Eli Lilly, Novartis In Breast Cancer... [Published Seeking Alpha - Apr 14 2014]
Interview: AstraZeneca’s oncology expert Susan ... [Published Pharma Letter - Apr 11 2014]
Lilly preps a PhIII study as breast cancer drug... [Published FierceBiotech - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib -... [Published Benzinga.com - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Yahoo! News - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Yahoo! Finance - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Zacks.com - Apr 08 2014]
1 Experimental Breast Cancer Drug You Need to Know [Published Motley Fool Discussion Boards - Apr 06 2014]
AstraZeneca Has a Promising Oncology Pipeline [Published American Journal of Managed Care - Mar 28 2014]
AstraZeneca ramps up oncology pipeline [Published Pharma Times - Mar 28 2014]
Combination treatment with strontium for the pr... [Published PharmCast - Jan 22 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
2014 Pipeline Report: The Sprint to Value [Published Pharmaceutical Executive - Nov 08 2013]
Estrogen receptors and methods of use [Published PharmCast - Oct 24 2013]
Half Yearly Pipeline Update [Published TrustNet - Aug 01 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.